In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era
for inflammatory bowel disease, leading to marked improvements in treatment options and …

Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …

Crohn's disease and ulcerative colitis are two idiopathic inflammatory disorders of the GI
tract. Manifestations of disease can be severe and lead to long term therapy with a variety of …

Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …

Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in
which dysregulated immune responses cause persistent inflammation of the gut mucosa …

In 1998, the US Food and Drug Administration granted regulatory approval to the first tumor
necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active …

Introduction: Anti-tumor necrosis factor (TNF) agents have changed the therapeutic
approach to inflammatory bowel disease (IBD). However, a considerable proportion of …

Inflammatory bowel disease (IBD), in particular Crohn's disease refractory to conventional
therapy, fistulizing Crohn's disease and chronic active ulcerative colitis, generally respond …

In the past decade, advances in the understanding of the pathogenesis of inflammatory
bowel disease have permitted the development of agents directed against rational …

The inflammatory bowel diseases (IBDs) are chronic incurable conditions that primarily
present in young patients. Being incurable, the IBDs may be part of the patient's life for many …